Long Term Metformin in Women With Polycystic Ovary Syndrome
The investigators analyzed collection data of 10 years for the efficacy of metformin on body mass, menstrual frequencies, metabolic and hormonal outcomes in women with polycystic ovary syndrome (PCOS) and BMI ≥ 25kg/m2.

Each patient's age and height were recorded at baseline. In addition each patient weight, waist circumference, menstrual regularity, fasting glucose, glucose after 120 minute oral glucose tolerance test, luteinizing hormone, follicle stimulating hormone , free and direct testosterone, androstenedione, sex hormone binding globulin, dehydroepiandrosterone sulfate were identified at baseline and at the every follow up visit where available.
Polycystic Ovary Syndrome
body weight, Primary outcome was change in body weight., The measurement is assessed in kilograms at the beginning and after every year of taking metformin for 10 years.|menstrual frequency, Primary outcome was change in menstrual frequency., The measurement is assessed in number of bleeds per year at the beginning and after every year of taking metformin for 10 years.|free testosterone, Primary outcome was change in levels of free testosterone., The measurement is assessed in nmol/L at the beginning and after every year of taking metformin for 10 years.|diabetes mellitus, Primary outcome was development of diabetes mellitus., The measurement of glucose in blood is assessed in mmol/L at the beginning and after every year of taking metformin for 10 years.
The investigators analyzed collection data of 10 years for the efficacy of metformin on body mass, menstrual frequencies, metabolic and hormonal outcomes in women with polycystic ovary syndrome (PCOS) and BMI ≥ 25kg/m2.

Each patient's age and height were recorded at baseline. In addition each patient weight, waist circumference, menstrual regularity, fasting glucose, glucose after 120 minute oral glucose tolerance test, luteinizing hormone, follicle stimulating hormone , free and direct testosterone, androstenedione, sex hormone binding globulin, dehydroepiandrosterone sulfate were identified at baseline and at the every follow up visit where available.